Maxim Group Issues a Buy Rating on Aeterna Zentaris

By Ryan Adsit

In a report released today, Jason Kolbert from Maxim Group reiterated a Buy rating on Aeterna Zentaris (NASDAQ: AEZS), with a price target of $11. The company’s shares opened today at $2.95.

Kolbert noted:

“We met with Aeterna Zentaris Management and reviewed Macrilen(Macimorelin) as the company moves closer to filing the NDA, expected in 3Q17. In this note (pages 2-4) we review some of the investigator’s slides from the P3 study.”

According to, Kolbert is ranked 0 out of 5 stars with an average return of -11.1% and a 31.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, ContraVir Pharmaceuticals Inc, and Brainstorm Cell Therapeutics.

Aeterna Zentaris has an analyst consensus of Moderate Buy.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company that is engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health. The company’s pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. It focuses on the development of Perifosine, Cetrotide, Ozarelix, AEZS-108 and AEZS-130. AEterna Zentaris was founded on September 12, 1990 and is headquartered in Montreal, Canada.